BJDX Bluejay Diagnostics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1704287 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY119.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-138.1%
ROA-107.8%
ROIC (approx.)-1,839.1%
Asset turnover—
Leverage & solvency
Liabilities / assets20.6%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $249,040 | — |
| Cost of revenue | — | — | — | $200,129 | — |
| Gross profit | — | — | — | $48,911 | — |
| R&D expense | $3.05M | $3.47M | $5.71M | $4.15M | $1.15M |
| SG&A expense | $3.91M | $3.69M | $4.31M | $451,421 | $1.79M |
| Operating income | -$6.95M | -$7.17M | -$10.31M | -$9.32M | -$3.23M |
| Interest expense | $839 | $823,028 | — | — | $6,360 |
| Net income | -$6.85M | -$7.72M | -$9.95M | -$9.30M | -$3.49M |
| EBITDA | -$6.88M | -$7.09M | -$9.66M | -$9.16M | -$3.08M |
| EPS (basic) | -15.25 | -456.75 | -3,631.48 | -9.22 | -0.41 |
| EPS (diluted) | -15.25 | -456.75 | -3,631.48 | -9.22 | -0.41 |
| Weighted avg. shares (diluted) | 449,043 | 45,848 | 2,741 | 1.01M | 8.52M |
| Banking | |||||
| Net interest income | — | — | — | — | -$367,459 |
| Balance sheet | |||||
| Cash & equivalents | $5.16M | $4.30M | $2.21M | $10.11M | $19.05M |
| Current assets | $5.46M | $4.90M | $3.22M | $11.79M | $20.66M |
| PP&E, net | $1.53M | $1.51M | $1.29M | $1.23M | $337,366 |
| Total assets | $7.12M | $6.66M | $4.87M | $13.52M | $21.02M |
| Current liabilities | $1.12M | $810,368 | $1.77M | $1.64M | $637,162 |
| Total liabilities | $1.14M | $927,924 | $1.97M | $1.98M | $637,162 |
| Shareholders' equity | $5.98M | $5.73M | $2.89M | $11.54M | $20.38M |
| Shares outstanding | 151,133 | 138,503 | 3,098 | 1.01M | 20.11M |
| Cash flow statement | |||||
| Operating cash flow | -$6.05M | -$7.82M | -$8.31M | -$7.74M | -$4.37M |
| Capital expenditure | $173,735 | $306,783 | $704,166 | $1.20M | $23,947 |
| Free cash flow | -$6.23M | -$8.13M | -$9.02M | -$8.94M | -$4.39M |
| Investing cash flow | -$173,735 | -$306,783 | -$704,166 | -$1.20M | -$23,947 |
| Financing cash flow | $7.09M | $10.22M | $1.11M | $8,075 | $22.53M |
| Depreciation & amortization | $74,182 | $75,618 | $648,708 | $156,598 | $145,719 |
| Stock-based compensation | $6 | $20,094 | $189,245 | $433,004 | $68,458 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.